Human albumin/von Willebrand factor - ViRexx

Drug Profile

Human albumin/von Willebrand factor - ViRexx

Alternative Names: Occlusin 50 Injection

Latest Information Update: 04 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViRexx Medical Corp
  • Class Antineoplastics; Blood coagulation factors; Coagulants; Plasma expanders
  • Mechanism of Action Platelet activating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 04 Feb 2014 Discontinued - Phase-I for Liver cancer in Canada (Intrahepatic)
  • 31 Dec 2008 No development reported - Phase-I for Liver cancer in Canada (Intrahepatic)
  • 23 Dec 2008 ViRexx Medical Corp has been acquired and merged into Paladin Labs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top